Veritas Intercontinental

About:

Genetics.The mission of Veritas Int. is to fulfill the promise of the human genome, empowering people to maximize quality and length of life

Website: http://www.veritasint.com

Twitter/X: Veritas_Gen_EL

Top Investors: Amadeus Capital Partners, Charme Capital Partners, Stemar Capital, Javier de Echevarría

Description:

The mission of Veritas Int. is to fulfill the promise of the human genome, empowering people to maximize the quality and length of life for themselves and their families. As the first company to introduce whole genome sequencing and interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science and technology while driving down the cost of the genome. Originally founded in 2014 by leaders in genomics from Harvard Medical School , Veritas Intercontinental was born in 2018 to deliver the promise of Whole Genome Sequencing outside United States. We have been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world’s most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018.

Total Funding Amount:

$25.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Madrid, Madrid, Spain

Founded Date:

2018-07-01

Contact Email:

info(AT)veritasint.com

Founders:

Javier de Echevarría, Luis Izquierdo López, Vincenzo Cirigliano

Number of Employees:

11-50

Last Funding Date:

2020-07-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai